AbbVie's Q2 earnings missed estimates, but revenue rose; insiders sold shares, and the stock closed at $229.19 with a $231.90 target.

Private Wealth Asset Management LLC and BankPlus Trust Department increased their AbbVie stakes in Q2, while executive vice presidents Azita Saleki-Gerhardt and Nicholas Donoghoe sold a combined 55,665 shares in August, netting over $11 million. AbbVie reported Q2 earnings of $2.97 per share, below the $3.24 estimate, though revenue rose 6.6% to $15.42 billion. The stock closed at $229.19 with a market cap of $404.88 billion and a forward P/E of 109.14. Analysts maintain a "Moderate Buy" rating with a $231.90 target. The company’s dividend yield is 2.9%, with an ex-dividend date of October 15, 2025.